Global Nicotine Addiction Treatment Market Growth Analysis By Omeros Corporation, Sosei Group Corporation, CV Sciences,Cerecor, Astraea Therapeutics LLC, Johnson & Johnson Services & others

Global nicotine addiction treatment market is rising gradually with a healthy CAGR in the forecast period of 2019-2026. Government policies and initiatives to offer a fund to many research institute and pharmaceuticals companies for developing novel therapy and increase dependency of tobacco products are the key factors for market growth

Ask For Complimentary Sample PDF| Request At

Market Definition: Global Nicotine Addiction Treatment Market

Nicotine is a stimulant drug and potent parasympathomimetic alkaloid found in the tobacco plant. Tobacco products contain nicotine is highly addictive causing craving for more of it. Nicotine addiction causes serious disease and death. Exposure of nicotine in adolescence can disrupt the brain development such as mood disorders. Nicotine replacement therapy is Over the Counter medication is most commonly used for smoking cessation. It reduces the withdrawal feelings by giving you a small controlled dose of nicotine and hence reduces the urge for smoke.

According to the statistics published in Alcohol and Drug Foundation, it is estimated up to 37.7% of people aged 14 years and above have used tobacco in the Australia. These growing cases of nicotine consumptions and high demand of novel therapies are the key drivers for market growth.

Competitive Analysis:

Global nicotine addiction treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global nicotine addiction treatment market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players:

Few of the major competitors currently working in the global nicotine addiction treatment market are Hager Biosciences, LLC, ADDEX THERAPEUTICS, Omeros Corporation, Sosei Group Corporation, CV Sciences, Inc, Cerecor, Inc, Astraea Therapeutics LLC, Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Pfizer Inc, Novartis AG, Sanofi, Dr. Reddy’s Laboratories Ltd, Teva Pharmaceutical Industries Ltd, Mylan N.V. , Axsome Therapeutics, Inc. and others.

Market Drivers

High prevalence of tobacco products consumptions acts as a market driver

Vulnerable adult population as adults are at high risk for nicotine addiction also drives the market growth

Increase in government initiatives and polices can also act as a market driver

Rapid adoption of newer formulations and novel dosage forms can boost the market growth

Market Restraints

Limited success of existing smoking cessation methods is also hampering the market growth

Preference of non-pharmacology therapies over pharmacology therapies can hinder the market growth

Patent expiry of major drugs and introduction of generic drugs of branded version is expected to restrict the growth of this market

Access Full Report @

Segmentation: Global Nicotine Addiction Treatment Market

By Type

Combustible Tobacco

Smokeless Tobacco

By Treatment Type

Nicotine Replacement Therapy

Psychological Therapy

By Drugs




Bupropion Hydrochloride

Off-label Drugs






By Product Type







By Route of Administration




By Drug Delivery System

Transdermal Drug Delivery System

Buccal Drug Delivery System


By End-Users



Specialty Clinics


By Geography

North America

South America



Middle East & Africa

Inquiry For Customize Report With Discount at :

Key Developments in the Market:

In June 2018, Omeros Corporation received approval from regulatory authority and ethics committee to initiate phase I clinical trial for its lead candidate PDE7, phosphodiesterase inhibitor for the treatment of all addictions including nicotine addiction and compulsive disorders. If successful, it will represent an immense and urgent unmet need for the treatment of nicotine addiction

In December 2017, Axsome Therapeutics, Inc entered into research collaboration with Duke University to develop AXS-05, a novel, oral, fixed-dose combination of dextromethorphan and bupropion. Under the deal terms, Duke University will be responsible for conducting preclinical research. This strategic alliance significantly contributes in solving the problem of tobacco addiction worldwide

Reasons to Purchase this Report

Current and future of global nicotine addiction treatment market outlook in the developed and emerging markets

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period

Regions/Countries that are expected to witness the fastest growth rates during the forecast period

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Data Bridge Market Research
Tel: +1-888-387-2818


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *